Literature DB >> 19637968

Resuscitation with hypertonic saline-dextran reduces serum biomarker levels and correlates with outcome in severe traumatic brain injury patients.

Andrew J Baker1, Shawn G Rhind, Laurie J Morrison, Sandra Black, Naomi T Crnko, Pang N Shek, Sandro B Rizoli.   

Abstract

In the treatment of severe traumatic brain injury (TBI), the choice of fluid and osmotherapy is important. There are practical and theoretical advantages to the use of hypertonic saline. S100B, neuron-specific enolase (NSE), and myelin-basic protein (MBP) are commonly assessed biomarkers of brain injury with potential utility as diagnostic and prognostic indicators of outcome after TBI, but they have not previously been studied in the context of fluid resuscitation. This randomized controlled trial compared serum concentrations of S100B, NSE, and MBP in adult severe TBI patients resuscitated with 250 mL of 7.5% hypertonic saline plus 6% dextran70 (HSD; n = 31) versus 0.9% normal saline (NS; n = 33), and examined their relationship with neurological outcome at discharge. Blood samples drawn on admission (<or=3 h post-injury), and at 12, 24, and 48 h post-resuscitation were assayed by ELISA for the selected biomarkers. Serial comparisons of biomarker concentrations were made by ANOVA, and relationships between biomarkers and outcome were assessed by multiple regression. On admission, mean (+/-SEM) S100B and NSE concentrations were increased 60-fold (0.73 +/- 0.08 microg/L) and sevenfold (37.0 +/- 4.8 microg/L), respectively, in patients resuscitated with NS, compared to controls (0.01 +/- 0.01 and 6.2 +/- 0.6, respectively). Compared with NS resuscitation, S100B and NSE were twofold and threefold lower in HSD-treated patients and normalized within 12 h. MBP levels were not significantly different from controls in either treatment arm until 48 h post-resuscitation, when a delayed increase (0.58 +/- 0.29 microg/L) was observed in NS-treated patients. Biomarkers were elevated in the patient group showing an unfavorable outcome. HSD-resuscitated patients with favorable outcomes exhibited the lowest serum S100B and NSE concentrations, while maximal levels were found in NS-treated patients with unfavorable outcomes. The lowest biomarker levels were seen in survivors resuscitated with HSD, while maximal levels were in NS-resuscitated patients with fatal outcome. Pre-hospital resuscitation with HSD is associated with a reduction in serum S100B, NSE, and MBP concentrations, which are correlated with better outcome after severe TBI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637968     DOI: 10.1089/neu.2008.0868

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  24 in total

1.  Inhibition of Neutrophils by Hypertonic Saline Involves Pannexin-1, CD39, CD73, and Other Ectonucleotidases.

Authors:  Yu Chen; Yi Bao; Jingping Zhang; Tobias Woehrle; Yuka Sumi; Stephan Ledderose; Xiaoou Li; Carola Ledderose; Wolfgang G Junger
Journal:  Shock       Date:  2015-09       Impact factor: 3.454

2.  Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: a systematic review and meta-analysis.

Authors:  Eric Mercier; Amélie Boutin; Michèle Shemilt; François Lauzier; Ryan Zarychanski; Dean A Fergusson; Lynne Moore; Lauralyn A McIntyre; Patrick Archambault; France Légaré; François Rousseau; François Lamontagne; Linda Nadeau; Alexis F Turgeon
Journal:  CMAJ Open       Date:  2016-07-22

Review 3.  Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations.

Authors:  Mauro Oddo; Daniele Poole; Raimund Helbok; Geert Meyfroidt; Nino Stocchetti; Pierre Bouzat; Maurizio Cecconi; Thomas Geeraerts; Ignacio Martin-Loeches; Hervé Quintard; Fabio Silvio Taccone; Romergryko G Geocadin; Claude Hemphill; Carole Ichai; David Menon; Jean-François Payen; Anders Perner; Martin Smith; José Suarez; Walter Videtta; Elisa R Zanier; Giuseppe Citerio
Journal:  Intensive Care Med       Date:  2018-03-02       Impact factor: 17.440

4.  The effects of hypertonic saline and nicotinamide on sensorimotor and cognitive function following cortical contusion injury in the rat.

Authors:  Andrea Quigley; Arlene A Tan; Michael R Hoane
Journal:  Brain Res       Date:  2009-09-23       Impact factor: 3.252

5.  The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.

Authors:  Andrea Kleindienst; Christian Schmidt; Hans Parsch; Irene Emtmann; Yu Xu; Michael Buchfelder
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-07-08

6.  Hematoma Enlargement Among Patients with Traumatic Brain Injury: Analysis of a Prospective Multicenter Clinical Trial.

Authors:  Adnan I Qureshi; Ahmed A Malik; Malik M Adil; Archie Defillo; Gregory T Sherr; M Fareed K Suri
Journal:  J Vasc Interv Neurol       Date:  2015-07

Review 7.  Fluid Management in Acute Brain Injury.

Authors:  Sandra Rossi; Edoardo Picetti; Tommaso Zoerle; Marco Carbonara; Elisa R Zanier; Nino Stocchetti
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-11       Impact factor: 5.081

8.  Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury.

Authors:  Edwin B Yan; Laveniya Satgunaseelan; Eldho Paul; Nicole Bye; Phuong Nguyen; Doreen Agyapomaa; Thomas Kossmann; Jeffrey V Rosenfeld; Maria Cristina Morganti-Kossmann
Journal:  J Neurotrauma       Date:  2014-01-09       Impact factor: 5.269

9.  Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients.

Authors:  Shawn G Rhind; Naomi T Crnko; Andrew J Baker; Laurie J Morrison; Pang N Shek; Sandro Scarpelini; Sandro B Rizoli
Journal:  J Neuroinflammation       Date:  2010-01-18       Impact factor: 8.322

Review 10.  ROC trials update on prehospital hypertonic saline resuscitation in the aftermath of the US-Canadian trials.

Authors:  Michael A Dubick; Pang Shek; Charles E Wade
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.